Cardiovascular health: an important component of cancer survivorship DOI Creative Commons
Siobhan Cleary, Stuart D. Rosen, Duncan C. Gilbert

et al.

BMJ Oncology, Journal Year: 2023, Volume and Issue: 2(1), P. e000090 - e000090

Published: Oct. 1, 2023

Advances in the detection and treatment of cancer have translated into improved survival rates a growing population survivors. These include those living with individuals free disease following treatment. Epidemiological studies demonstrate that survivors are at an increased risk cardiovascular (CVD), (CV) mortality overtaking some tumour types. Cancer CVD share common aetiological factors, for example, age, tobacco use obesity, as well shared inflammatory pathogenesis. The CV risks mediastinal radiotherapy chemotherapy, first observed 1970s anthracyclines, long been appreciated. More recently, targeted anticancer therapeutics (human epidermal growth factor receptor-2 therpies, vascular endothelial inhibitors, second/third-generation BCR-ABL multiple myeloma therapies combination RAF MEK inhibitors particular) immunotherapies added to burden treatment-related toxicity. Additionally, therapy may indirectly impact on health by decreasing physical activity, increasing weight gain accelerating ageing process. Improving overall outcomes considering cardiological prevention management survivorship is area interest. assessment recommended post-cancer accordance primary guidelines. European Society Cardiology 2022 guidelines also recommend enhanced surveillance after treatments moderate high consequences. aim this article provide overview interconnections between CVD, review current recommendations, highlight key areas ongoing future research.

Language: Английский

Cardiovascular disease and cancer: shared risk factors and mechanisms DOI
Nicholas S. Wilcox,

Uri Amit,

Jacob B. Reibel

et al.

Nature Reviews Cardiology, Journal Year: 2024, Volume and Issue: 21(9), P. 617 - 631

Published: April 10, 2024

Language: Английский

Citations

75
Cardiovascular Considerations Before Cancer Therapy DOI Creative Commons
Zahra Raisi‐Estabragh, A. Murphy,

Sivatharshini Ramalingam

et al.

JACC CardioOncology, Journal Year: 2024, Volume and Issue: 6(5), P. 631 - 654

Published: Sept. 24, 2024

Language: Английский

Citations

7
Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies DOI
Sanne de Wit, Claire Glen, Rudolf A. de Boer

et al.

Cardiovascular Research, Journal Year: 2022, Volume and Issue: 118(18), P. 3451 - 3466

Published: Aug. 24, 2022

Heart failure (HF) and cancer are the leading causes of death worldwide accumulating evidence demonstrates that HF affect one another in a bidirectional way. Patients with at increased risk for developing cancer, is associated accelerated tumour growth. The presence malignancy may induce systemic metabolic, inflammatory, microbial alterations resulting impaired cardiac function. In addition to pathophysiologic mechanisms shared between HF, overlaps also exist pathways required normal physiology Therefore, these explain cardiotoxicity as result targeted anti-cancer therapies. This review provides an overview involved connection specifically focusing upon current 'hot-topics' mechanisms. It subsequently describes therapies cardiotoxic potential overlap their targets

Language: Английский

Citations

27
Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA) DOI Creative Commons
Firas Kreidieh, Jennifer L. McQuade

American Heart Journal Plus Cardiology Research and Practice, Journal Year: 2024, Volume and Issue: 40, P. 100374 - 100374

Published: March 1, 2024

Novel immune and targeted therapies approved over the past 2 decades have resulted in dramatic improvements cancer-specific outcomes for many cancer patients. However, of these agents can induce cardiovascular toxicity a subset The field cardio-oncology was established based on observations that anti-neoplastic chemotherapies mantle radiation lead to premature cardiomyopathy survivors. While conventional chemotherapy, therapy, all result adverse events, mechanisms, timing, incidence events are inherently different. Many effects converge upon coronary microvasculature involve, through endocardial endothelial cells, more direct effect close proximity cardiomyocyte with cellular communication signaling pathways. In this review, we will provide an overview emerging paradigms Cardio-Oncology, particularly role mediating important therapies. As number patients treated novel grows exponentially subsequently long-term survivors dramatically increases, it is critical cardiologists cardiology researchers recognize unique potential toxicities agents.

Language: Английский

Citations

5
Cardiotoxicity of BRAF/MEK Inhibitors DOI Creative Commons
Claire Glen,

Sarah Adam,

Kirsty McDowell

et al.

JACC CardioOncology, Journal Year: 2023, Volume and Issue: 5(5), P. 628 - 637

Published: June 7, 2023

Rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors have revolutionized treatment for patients with BRAF-mutated melanoma. Although left ventricular systolic dysfunction associated these therapies has been reported in clinical trials, the real-world incidence is poorly defined, as are risk factors its development.This study sought to characterize incidence, time course, cancer therapy-related cardiac (CTRCD) melanoma receiving BRAF MEK inhibitors.Patients treated at a hospital network between June 1, 2017, 30, 2020, were included retrospectively. CTRCD was defined mild, moderate, or severe according International Cardio-Oncology Society (ICOS) definitions. Baseline cardiotoxicity stratification performed using Heart Failure Association/ICOS tool.Of 63 included, 27% developed (17% mild 10% moderate). No symptomatic heart failure. occurred most frequently considered be "low" "medium" baseline of (82%). The ejection fraction global longitudinal strain not different who moderate vs those did not. Left internal diameters diastole systole larger compared (left diameter diastole: 4.9 ± 0.6 cm 4.3 cm; P = 0.023; systole: 3.3 0.4 2.8 0.5 0.039).BRAF inhibitor-associated common. utility tool appears limited this group, better prediction tools needed. long-term consequences CTRCD, particularly warrant evaluation prospective studies.

Language: Английский

Citations

12
Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation DOI Open Access

Lloyd Butel-Simoes,

Tatt Jhong Haw,

Trent Williams

et al.

Hypertension, Journal Year: 2023, Volume and Issue: 80(4), P. 685 - 710

Published: Feb. 9, 2023

Cardiovascular disease and cancer are 2 of the leading causes death worldwide. Although improvements in outcomes have been noted for both entities, success therapies has come at cost times very impactful adverse events such as cardiovascular events. Hypertension both, a side effect well risk factor cardiotoxicity therapies. Some these dynamics keeping with role hypertension not only heart failure, but also development coronary cerebrovascular disease, kidney its association higher morbidity mortality overall. Other aspects molecular mechanisms underlying amplification acute long-term anthracyclines increase blood pressure various therapeutics remain to be elucidated. In this review, we cover latest clinical data regarding across spectrum novel anticancer known or postulated pathophysiological mechanisms. Furthermore, review implications drugs commonly associated anthracyclines. An outline management strategies, including pharmacological lifestyle interventions models care aimed facilitate early detection more timely patients survivors concludes which overall aims improve cancer-specific outcomes.

Language: Английский

Citations

11
Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer DOI Open Access
Sara Torresan,

Martina Bortolot,

Elisa De Carlo

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(2), P. 554 - 554

Published: Jan. 10, 2025

The treatment of Non Small Cell Lung Cancer (NSCLC) has been revolutionised by the introduction targeted therapies. With improvement response and frequently overall survival, however, a whole new set adverse events emerged. In fact, due to peculiar mechanism action each one tyrosine kinase inhibitors other therapies, every drug its own specific safety profile. addition, this profile could not fully emerge from clinical trials data, as patients in practice usually have more comorbidities frailties. Cardiotoxicity is well-known established event anti-cancer However, only recently it become central topic for therapies NSCLC, unknown real range frequency. Management toxicity begins with prevention, must balance need continuing an effective anticancer versus low risk even fatal preservation long-term quality life. aim review summarise current knowledge focusing on currently used NSCLC.

Language: Английский

Citations

0
Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association DOI
Thomas D. Ryan, James E. Bates,

Karen E. Kinahan

et al.

Circulation, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

The field of cardio-oncology has expanded over the past 2 decades to address ever-increasing issues related cardiovascular disease in patients with cancer and survivors. There is increasing recognition that nearly all treatments pose some short- or long-term risk for development pediatric may be especially vulnerable because young age at treatment expected long life span afterward. Anthracycline chemotherapy chest-directed radiotherapy are most well-studied cardiotoxic therapies, dose reduction, use cardioprotection anthracyclines, modern approaches have contributed improved outcomes Newer such as small-molecule inhibitors, antibody-based cytotoxic therapy, immunotherapy options previously difficult-to-treat cancers but also revealed new profiles. Application effective surveillance strategies survivors been a focus practitioners researchers, whereas prevention extant still developing. Incorporation an equitable manner appropriate transition from adult care will greatly influence health-related growing population childhood disease.

Language: Английский

Citations

0
Chemically Induced Hypertension: Antineoplastic Agents Associated with High Blood Pressure DOI
Emily Moss, Anushree C. Shirali

Updates in hypertension and cardiovascular protection, Journal Year: 2025, Volume and Issue: unknown, P. 79 - 91

Published: Jan. 1, 2025

Language: Английский

Citations

0
Management of selumetinib-associated toxicity in children with neurofibromatosis type 1 and plexiform neurofibromas DOI
Yu. V. Dinikina,

N. S. Dekhtyareva

Podderživaûŝaâ terapiâ v onkologii., Journal Year: 2025, Volume and Issue: 2(1), P. 30 - 43

Published: April 7, 2025

According to the statistics of major studies, neurofibromatosis is one most common genetic diseases associated with tumor syndrome incidence rate 1 case per 3000–6000 people. The benign neoplasms typical for type are plexiform and cutaneous neurofibromas which amount up 95 % all NF1-associated tumors.Selumetinib a selective mitogen-activated protein kinase types 2 inhibitor showed promising results in treatment inoperable symptomatic neurofibromas. Objective response selumetinib was 68 %. In 2021, registered Russian Federation included into State Register Medicinal Remedies. It important consider that development clinically significant adverse events during this therapy can cause drug discontinuation, reduce patients’ adherence as result negatively affect overall effectiveness.The article presents review selumetinib, their prevention options based on current international guidelines.

Language: Английский

Citations

0